Poly Medicure Limited has informed the Exchange about Grant of 3,400 Stock options under Poly Medicure Employee Stock Option Scheme, 2020.
POLYMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Poly Medicure Limited's board, at its meeting on August 8, 2025, approved unaudited financial results for Q1 FY26 (quarter ended June 30, 2025). On a standalone basis, revenue from operations rose to ₹38,404.67 lakhs from ₹36,742.47 lakhs in Q1 FY25, while profit after tax jumped to ₹8,792.89 lakhs from ₹7,230.25 lakhs, a year-on-year increase of about 22%. Consolidated revenue stood at ₹40,321.07 lakhs with PAT of ₹9,308.29 lakhs (vs ₹7,403.94 lakhs), translating to consolidated EPS of ₹9.19. The board also re-appointed two independent directors (Mr. Amit Khosla and Ms. Sonal Mattoo) for five-year terms and appointed Mr. Pankaj Kumar Gupta as a new Executive Director. Additionally, 3,400 stock options were granted to eligible employees under the ESOP 2020 scheme at an exercise price of ₹100 per share, and M/s Jai Prakash & Company was re-appointed as Cost Auditor for FY 2025-26.
Strong Q1 results with ~22% standalone profit growth and improving margins should be viewed positively by shareholders, though the small ESOP grant of 3,400 shares is a routine, non-dilutive event. Director continuity and the elevation of an internal operations leader to Executive Director signal stable governance.